ImmunityBio Investors Face May 26 Deadline to Seek Lead Role in Securities Case

Overview

• The putative class action, Douglas v. ImmunityBio in the Central District of California, covers trades from January 19, 2026 through March 24, 2026.
• The FDA's March 13, 2026 letter said a TV ad and a podcast were false or misleading by implying Anktiva could cure or prevent all cancer.
• Anktiva is approved only with Bacillus Calmette‑Guérin to treat non‑muscle invasive bladder cancer, which the FDA said the promotions failed to clearly present.
• Following publication of the warning letter on March 24, 2026, ImmunityBio's shares fell more than 21 percent and lost nearly $2 billion in market value.
• Robbins Geller, Rosen Law Firm, Faruqi & Faruqi, Hagens Berman, and The Gross Law Firm are recruiting investors as the court considers lead‑plaintiff motions due May 26, 2026.